# Ruishi Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruishi-health

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.svision100.com
- Total disclosed funding: $21M
- Latest round: Series A (Jun 30, 2025)
- Investors on record: 5

## About

Founded in 2017 and headquartered in Beijing, China, Ruishi Health has developed into a platform company combining advanced optical technology with medical expertise for myopia management. In 2018, it began collaborations with Beijing Tongren Hospital, the National Ophthalmic Diagnosis and Treatment Engineering Technology Center, and Beijing Institute of Technology, launching its remote image light screen product line. The company holds a national Class II medical device registration certificate, and its products have undergone multi-center clinical trials with institutions such as Beijing Tongren Hospital, Sichuan Huaxi Hospital and Wenzhou Medical University Eye Hospital. In August 2025, the firm closed a round of venture funding from new investor Advanced Manufacturing Investment, with participation from returning investor Sinovation Ventures.The main product of the company is myopia prevention and control remote image light screen. The nearsightedness prevention and control remote image light screen adopts technologies such as analog remote high-definition imaging, digital spectral structure, digital defocusing and fuzzy stimulation to protect the user's vision. The company generates revenue through the sale of medical devices for myopia prevention and control, associated software and AI-driven management services and ongoing visual health programs offered via its professional and retail partner network. The company will use the funding raised from the latest round to support Class III medical device registration applications, upgrade and iterate core products, strengthen sales and brand building and continue investment in product R&D.

## Funding rounds

- Series A, Jun 30, 2025 — JC Capital
- Series A, Aug 9, 2023, $14M — Sinovation Ventures, Sinopharm-CICC Capital, BRV Aster, Yunnan Botanee Bio-Technology Group
- Series A, Dec 14, 2022, $7.2M — Sinopharm-CICC Capital, BRV Aster

## Investors

- Sinopharm-CICC Capital (https://capitalatlas.ai/funds/sinopharm-cicc-capital) — Series A
- BRV Aster — Series A
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A
- Yunnan Botanee Bio-Technology Group — Series A
- JC Capital (https://capitalatlas.ai/funds/jc-capital) — Series A